Update on Lu AA21004 clinical development programme in major depressive disorder (MDD)
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) and Takeda Pharmaceutical Company Limited (Takeda) jointly have announced headline results from the first three clinical trials in the phase III development programme with Lu AA21004 in major depressive disorder (MDD). Previously reported clinical phase II data showed equal efficacy with the 5 and 10 mg doses.
World Health Organization grants Global Prequalification to GSK's Rotarix⢠vaccine
- Details
- Category: GlaxoSmithKline
The World Health Organisation (WHO) has awarded global prequalification to GlaxoSmithKline Biologicals' vaccine against rotavirus, Rotarix™.Additionally, the WHO's Strategic Advisory Group of Experts (SAGE) also recommended that rotavirus vaccination be included in all national immunisation programmes.
New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate and Treatment Failure
- Details
- Category: Amgen
Amgen Inc. (Nasdaq: AMGN) released the results of a new study comparing Nplate(R) (romiplostim) to the medical standard of care (SOC) in non-splenectomised adult patients with chronic immune thrombocytopenic purpura (ITP). Chronic ITP is a serious autoimmune disorder characterised by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events.
AstraZeneca and Abbott Extend Relationship to Include Co-Promotion of Trilipix
- Details
- Category: AstraZeneca
AstraZeneca and Abbott have entered into an agreement for AstraZeneca to co-promote Abbott's TRILIPIX, a medication for use alone or in combination with a statin to treat certain lipid disorders. Under the terms of the agreement, AstraZeneca will obtain the non-exclusive right to co-promote TRILIPIX alongside Abbott in the United States, excluding Puerto Rico. Specific financial terms were not disclosed.
FDA approves Reclast® to prevent osteoporosis in postmenopausal women
- Details
- Category: Novartis
Reclast® (zoledronic acid 5 mg) Injection[*] has been approved by the US Food and Drug Administration (FDA) as the first and only therapy to prevent postmenopausal osteoporosis for two years with a single dose[1].
Schering-Plough Announces European Filing of SYCREST(R) (asenapine)
- Details
- Category: Product
Schering-Plough Corporation (NYSE: SGP) announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for SYCREST(R) (asenapine) sublingual tablets for the treatment of schizophrenia and manic episodes associated with bipolar I disorder.
New study first ever to directly compare once-daily Levemir® with another basal insulin analogue
- Details
- Category: Novo Nordisk
Novo Nordisk has announced the first patient visit in a new head-to-head clinical trial of once-daily Levemir® against insulin glargine. This study is the first time the two basal insulins will be directly compared in an exclusively once-daily regimen. Outcomes measured in the study will include efficacy, effect on weight and hypoglycaemia in type 2 diabetes patients.
More Pharma News ...
- Genzyme Completes Transaction with Bayer HealthCare
- AstraZeneca and Merck & Co., Inc. Form Pioneering Collaboration
- Bayer and Onyx Initiate Phase III Trial of Nexavar® in Non-small Cell Lung Cancer
- Bayer and Onyx Initiate Phase III Trial of Nexavar® in Non-small Cell Lung Cancer
- Abbott Named One of the Top 10 Companies for Scientists
- AstraZeneca Regulatory Update on Seroquel XR for the Treatment of Major Depressive Disorder
- Phase III Trial Started to Evaluate Combination Therapy of Nexavar® and Tarceva®